Prevalence and Onset of Hepatotoxicity Caused by Anti-Tuberculosis Drugs on Pulmonary TB Patients in Wangaya General Hospital Denpasar – Bali in 2016

Wayan Evie Frida Yustin, Ida Ayu Jasminarti Dwi Kusumawardani, Ni Wayan Candrawati, Ida Bagus Ngurah Rai

Abstract


Introduction: As tuberculosis (TB) endemic country, TB becomes a community health problem in Indonesia. Data from the Global TB Report in 2016 showed that Indonesia is the second most country with TB burden after India. WHO and the Ministry of Health issue a TB prevention program based on the End TB Strategy aimed to reduce morbidity, mortality, and disability due to TB. One of the challenges faced in the management of TB is the side effects of the anti-tuberculosis drug. Hepatotoxicity is the most common side effect. Aims: This study aims to determine the prevalence and onset of anti-TB drug-induced hepatotoxicity in TB patients after receiving the anti-TB drug in Wangaya Hospital Denpasar Bali. Method: This study used a cross-sectional method by obtaining secondary data of pulmonary TB patients visiting the pulmonary clinic in Wangaya General Hospital from January to December 2016. Result: Of 77 subjects, fifty-six percent of them were men. The highest prevalence was found in the 41-50 years age group (26.9%), while the lowest was found in the 81-90 years age group (1.2%). Anti-TB drug-induced hepatotoxicity occurred in 6.5% of subjects. The most frequent onset of hepatotoxicity occurred within the second week of medication. Anti-TB drug-induced hepatotoxicity occurred in 6.5% of subjects. The most frequent onset of hepatotoxicity occurred within the second week of medication. Conclusion: Based on this study, we suggest a liver function test before and after two weeks of an anti-TB drug.


Keywords


Prevalence, Tuberculosis, Pulmonary TB, Hepatotoxicity, ANTI-TB DRUG

Full Text:

PDF

References


Kementerian Kesehatan Republik Indonesia. Petunjuk teknis pemeriksaan TB menggunakan tes cepat molekuler. Jakarta: Kementerian Kesehatan RI; 2017.

Kementerian Kesehatan Republik Indonesia. Tuberkulosis: Temukan Obati Sampai Sembuh. Jakarta; 2016.

World Health Organization (WHO). WHO treatment guidelines for drugresistant tuberculosis. Geneva: World Health Organization’s; 2016.

World Health Organization (WHO). Global Tuberculosis Report 2019. 2019.

Soedarsono, Riadi ARW. Tuberculosis drug-induced liver injury. J Respirasi. 2020;6(2):49–54.

Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Manajemen dan Tatalaksana Tuberkulosis (TB). Jakarta: Kementerian Kesehatan RI; 2016.

Kemenkes RI. Pedoman Nasional Penangulangan Tuberkulosis. Jakarta: Kementerian Kesehatan RI; 2014.

Song JH, Yoon S, Park TY, et al. The clinical impact of durg-induced hepatotoxicity on anti-tuberculosis therapy: A case control study. Respir Res. 2019;20:1–8.

Fishman JA, Grippi MA, Kotloff RM, et al. Fishman’s Pulmonary Disease and Disorders Fifth Edition. New York: Elsevier Saunder; 2016.

Yu CY; Mao YM; Chen JJ; et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41.

Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. Int J Mycobacteriology. 2016;5:14–20.

Saskar S, Ganguly A, Sunwoo HH. Current overview of anti-tuberculosis drugs: Metabolism and toxicities. Mycobact Dis. 2016;6(2):1–6.

Mirlohi M, Ekrami A, Shirali S, et al. Pourmotahari F. 2016. Hematological and liver toxicity of anti-tuberculosis drugs. Electron Physician. 2016;8(9):3005–10.

Jeong I, Park J, Cho Y, et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 2015;30:167–72.

Kasper; Denis L; et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.

Aru W; Idrus A; Marcelus S; et al. Buku Ajar Ilmu Penyakit Dalam. 5th ed. Jakarta: Interna; 2013.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;30(20):1–40.

Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3–13.

Zhao H, Wang Y, Zhang T, et al. Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study. Med Sci Monit. 2019;26:1–8.

Ambreen K, Sharma R, Singh KP, et al. Anti-tuberculosis drug-induced hepatotoxicity: A review. Int J Adv Biotechnol Res. 2014;5(3):423–37.

Anggraini D, Laboratory Examination in Hepatocellular carcinoma. Health & Medical Journal. 2019 1(2): 50-3. https://doi.org/10.33854/heme.v1i2.241.g191

Anggraini, D., & Oktora, M. Z. (2021). Hematology Profile of Tuberculosis Lymphadenitis Patients at Siti Rahmah Hospital, Padang, Indonesia. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 27(3), 271-275.




DOI: https://doi.org/10.33854/heme.v4i3.998

DOI (PDF): https://doi.org/10.33854/heme.v4i3.998.g438

Refbacks

  • There are currently no refbacks.


Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.